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ABSTRACT  1 
 2 
Background: Observational studies have reported conflicting results on the impact of mammography 3 
service screening programmes on advanced breast cancer rate (ABCR), a correlation that was firmly 4 
established in randomized controlled trials. We reviewed and summarized studies of the effect of 5 
service screening programmes in the European Union on ABCR and discussed their limitations. 6 
Methods: The PubMed database was searched for English language studies published between 01-7 
01-2000 and 01-06-2018. After inspection of titles and abstracts, 220 of the 8644 potentially eligible 8 
papers were considered  relevant. Their abstracts were reviewed by groups of two authors using 9 
predefined criteria. Fifty studies were selected for full paper review, and 22 of these were eligible. A 10 
theoretical framework for their review was developed. Review was performed using a ten-point 11 
checklist of the methodological caveats in the analysis of studies of ABCR and a standardised 12 
assessment form designed to extract quantitative and qualitative information. 13 
Results: Most of the evaluable studies support a reduction in ABCR following the introduction of 14 
screening. However, all studies were challenged by issues of design and analysis which could at least 15 
potentially cause bias, and showed considerable variation in the estimated effect. Problems were 16 
observed in duration of follow-up time, availability of reliable reference ABCR, definition of advanced 17 
stage, temporal variation in the proportion of unknown-stage cancers, and statistical approach.  18 
Conclusions: We conclude that much of the current controversy on the impact of service screening 19 
programmes on ABCR is due to observational data that were gathered and/or analysed with  20 
methodological approaches which could not capture stage effects in full. Future research on this 21 
important early indicator of screening effectiveness should focus on establishing consensus in the 22 
correct methodology. 23 
KEY WORDS  24 
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BACKGROUND  1 
 2 
A long follow-up is required to assess the impact of mammography screening programmes on breast 3 
cancer mortality. The advanced breast cancer incidence rate (hereafter briefly referred to as 4 
advanced breast cancer rate, ABCR) can potentially be used as an earlier indicator of the 5 
effectiveness of a screening programme.  Moreover, since tumour stage at diagnosis is independent 6 
of treatment, except for neoadjuvant therapy, analysis of trends in ABCR allows the effects of early 7 
detection to be disentangled from those of improvements in treatment [1]. The correlation between 8 
reductions in breast cancer mortality and ABCR has been firmly established on the basis of screening 9 
trials [2]. In a pooled analysis of data from eight trials, the decrease in the risk of advanced breast 10 
cancer and the decrease in the risk of dying from the disease were approximately proportional [1, 3]. 11 
It is clear that screening is associated with a reduction in the proportion of advanced stage cancers 12 
[4]. However, observational studies published over the last 15-20 years have yielded conflicting 13 
results on the association between the introduction of population-based service screening 14 
programmes and changes in ABCR, i.e. the absolute incidence of advanced stage disease [3, 5]. 15 
Nevertheless, the evaluation of the change in the incidence of advanced breast cancer cases is 16 
relevant in service screening outcome research. An apparent lack of this change has been considered 17 
by some as evidence of the lack of mammography screening programmes’ effectiveness [5-8].   18 
The objectives of the current study were (a) to review studies of the effect of mammography 19 
screening programmes in Europe on ABCR, and (b) to summarize their limitations and the extent to 20 
which they contribute to the evidence on screening effectiveness. 21 
 22 
METHODS 23 
 24 
Search strategy and selection criteria  25 
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A systematic search of PubMed with the search terms ‘cancer stage’, ‘screening’, ‘breast cancer’, 1 
‘incidence’, and ‘mammography’ was performed to identify papers published from January 2000 until 2 
May 2013 (details in Appendix) and later updated to June 2018. Only papers in English evaluating 3 
European programmes were reviewed. The search strategy was built using 7 key papers  4 
[9-15].  5 
Abstracts from the papers identified were reviewed by two from a group of four reviewers 6 
(MB, PA, SM, LB) and papers for full review were selected using the following general criteria: (a) the 7 
study represented original data and estimated the impact of a current regional or national 8 
population-based screening programme in Europe; (b) definition of advanced disease was based on 9 
breast cancer size, nodal status and/or stage at diagnosis of breast cancer; (c) the analysis included at 10 
least some of the age groups between 50 and 69; (d) the study used an observational research design 11 
comparing rates or proportions of advanced stage cancers; and (e) an uninvited and/or unscreened 12 
control population was available. This included the pre-screening years for the population targeted 13 
for screening in the study. Comparisons only of attenders vs non-attenders were not included. We 14 
focused the review on European programmes to add evidence on advanced breast cancer to the 15 
European balance sheet of benefits and harms as an outcome to the work of the Euroscreen reviews 16 
of observational mortality studies [16]. 17 
 18 
Definition of advanced breast cancer   19 
Tumour staging criteria vary across studies and even studies using the UICC TNM classification [17] 20 
show little agreement in their definition of advanced breast cancer. Theoretically, the benefit of 21 
screening is limited to screen-detected cases, either earlier within the same stage or at an earlier 22 
stage. However, using stage in itself has a disadvantage due to the stage migration bias caused by the 23 
introduction of sentinel lymph node dissection [18] and by changes in coding and classification 24 
practices [19]. In this respect, using only the pT information as a proxy for the diameter of the lesion 25 
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is the most direct link to radiological detection and less influenced by trends in missing data and 1 
changes in coding and classification practices, even though it cannot show within-stage shifts in 2 
diameter. It is therefore the least biased option to define advanced breast cancer detection. Tumour 3 
size (measured in mm), even though put forward by some authors as an indicator of diagnostic 4 
anticipation [20], has never been confirmed as such and is often inaccurate since pathologists tend to 5 
round to the nearest multiple of five (terminal digit preference bias) [21].   6 
 7 
Theoretical framework and checklist   8 
We designed an assessment form to extract detailed quantitative and qualitative information, the 9 
study design, completeness of information and results from the selected papers in a standardized 10 
fashion.  11 
The expected effect of mammography  service screening programmes on ABCR is best 12 
understood looking at the randomized controlled trials (RCTs) as a reference, as previously described 13 
[1-3]. Based on the RCTs, the ABCR in the population invited to screening, usually from age 50, is 14 
expected to remain stable or slightly increase when the programme starts. The increasing incidence, 15 
in comparison with the prescreening incidence rate, is due to the intra-stage shift. This means that 16 
screening will detect advanced cancer cases earlier, but still within the same stage as in the absence 17 
of screening. After the prevalence screening, assuming a 100% sensitivity, the advanced cancer cases 18 
will be diagnosed as interval cancers, if fast growing, or are expected to be detected earlier at 19 
subsequent rounds. For this reason, the expectation is a reduction of the ABCR 2-3 years after the 20 
start (Figure 1). The advanced cancer cases that are detected earlier through screening than they 21 
would have been in the situation without screening are the ones which should benefit. The ABCR 22 
should thus decrease from the time of prevalent screening (time 0) to a lower level than the 23 
expected, reaching a plateau after a few years, because screening will move diagnoses of breast 24 
cancer cases forward in time as long as the programme continues. If screening stops, e.g. at 65 or 69 25 
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years in most European screening programmes, the ABCR is expected to increase again, rising after 1 
some years to the prescreening level (age-specific) . 2 
 3 
 Figure 1 Insert here –  4 
 5 
In order to discern this pattern of occurrence, the ABCR with or without screening will be 6 
best observed in a study where individual women are followed over time, and an unconfounded 7 
comparison of screening with non-screening incidence is available. In order to assess the extent to 8 
which studies achieve or approximate this ideal situation, we developed a ten-point checklist of the 9 
main methodological issues with which such studies of ABCR have to contend, logically derived from 10 
the above described theoretical framework (Table 2).  The checklist is based on epidemiological 11 
principles of observational studies as applied to screening [22] and previous research experience,  12 
including knowledge of the relevant literature from outside of Europe [6, 7, 23-26] and findings of 13 
the Euroscreen reviews of observational mortality studies (trend studies, incidence-based mortality 14 
studies, and case-control studies) [27, 28]. The methodological issues identified using the ten-point 15 
checklist, their definitions, and their consequences on design, likely accuracy, and results of studies 16 
are presented in Table 2. This in turn highlights the main potential departures of studies from the 17 
ideal design of a study of the temporal association between mammography screening programmes 18 
and incidence of advanced stage breast cancer, and indicates the major issues of interpretation of 19 
the results.  20 
The checklist items included: 4 complications related to the timescale of screening 21 
introduction, periods of exposure and observation, and transient prevalence screen effects; 3 to 22 
endpoint definition, stage migration and completeness of stage data; 1 to difficulties of formal 23 
inference; and 2 to the inevitable problem of incomplete information on what the incidence of breast 24 
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cancer overall and of advanced disease would have been in the absence of the screening 1 
programme. 2 
 3 
Presentation of results 4 
Due to the heterogeneity in methodology and endpoints used in the studies, no attempt was made 5 
to produce a pooled estimate of the effect of screening on ABCR. Instead, we reported details of 6 
methods and results of each study individually in Table 1. We looked for data on screening coverage 7 
and attendance rates from other sources as well, if the selected study did not provide that 8 
information.  9 
 10 
RESULTS   11 
 12 
Selection of studies 13 
The search strategy identified 8644 English-language papers of which 220 were considered  relevant 14 
based on title and abstract (Figure 2), including both studies of incidence rates and those of 15 
proportions of advanced cancers.  16 
  17 
 Insert Figure 2 here – 18 
 19 
Based on the selection criteria, 38 studies were included, and a further 24 were identified as 20 
possible inclusions. For the latter group, full papers were assessed by two different reviewers, with 21 
arbitration by a third (SD) where necessary, which resulted in the inclusion of 4 studies. In addition, 22 
the abstract of one paper suggested by a co-author was assessed and included for review. In total, 23 
after adding the 7 key papers, 50 studies were included for full paper review by the two reviewers 24 
who had not assessed the abstract. We also manually searched the reference lists of these papers 25 
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and identified 10 references that fulfilled the inclusion criteria but had not been identified by the 1 
search strategy. Review of the full papers for these references resulted in the inclusion of an 2 
additional 5 studies. Differences between reviews were resolved through consensus by all four 3 
reviewers. Of the 60 full paper reviews in total, 22 studies were found eligible for inclusion in a 4 
comparison of incidence rates as the outcome measure [8, 12-15, 19, 29-44]. A further 9 studies 5 
were comparisons of proportions of advanced cancers and not included in the current review. Of the 6 
29 papers excluded, 21 lacked a suitable control group, 3 were not related to population-based 7 
screening and 5 were excluded for other reasons (no data for 50-69 (n=2), no tumour stage data 8 
(n=1), not European Union (n=1) no original data (n=1)).  9 
 10 
Study generalities  11 
These are shown in Table 1. The 22 eligible studies were from Norway (n=5), Italy (n=5), the 12 
Netherlands (n=4), Denmark (n=2), Sweden, Finland, Germany, United Kingdom (UK), Ireland, and 13 
France. There were 9 nation-wide studies, four from Norway [19, 36, 38, 39], two from the 14 
Netherlands [14, 41], two from Denmark [8, 37], and one from Finland [34].  15 
  16 
 Insert Table 1 here – 17 
 18 
Programme characteristics    19 
In most studies, the target age range was 50-69 years [8, 14, 15, 19, 29, 30, 32, 35-41, 44] or wider 20 
[12, 31, 43]. The papers from Finland, the West Midlands region of the UK, and Ireland reported 21 
programmes aimed at women aged 50-59 years [34] and 50-64 years [13, 42]. The target age of the 22 
Swedish programme varied locally between 40 and 74 years [33]. The size of the target population, 23 
often not reported, was between 500,000 and 1,000,000 in the national Dutch study [14], in the 24 
Danish studies [8, 37] and in one Italian study [15], and exceeded 1,000,000 in the study from 25 
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Sweden [33] and in a second study from Italy [32]. The screening interval was 24 months except in 1 
the West Midlands (36 months) [13]. The start of screening programmes ranged from the early/mid 2 
1970s in Florence, Utrecht, and Nijmegen [14, 29] to 2005 in the Münster district (Germany) [40]. 3 
The time period of observation of breast cancer incidence was between the second half of 1980s and 4 
the first half of the current decade in most studies.  5 
    6 
Study design    7 
The methods of analysis varied from the provision of purely descriptive information to the evaluation 8 
of the magnitude and statistical significance of observed changes in ABCR. We assigned the design of 9 
the studies that evaluated the magnitude of effect to four broad categories:  10 
(1) comparison of ABCR before and after the introduction of screening using different endpoints, i.e., 11 
annual percent change (APC), percent reduction in ABCR, absolute reduction in ABCR, incidence rate 12 
ratio (IRR), relative risk (RR), excess RR, slope value calculated from a log-linear Poisson regression 13 
model, and observed:expected ratio, or simply by juxtaposition of rates  [8, 12, 15, 19, 29, 30, 32-40, 14 
43, 44];  15 
(2) comparison of ABCR between each year after the introduction of screening and the prescreening 16 
years using the estimated annual percent change (EAPC) [14, 31];   17 
(3) calculation of the EAPC after the introduction of screening without information on prescreening 18 
years [13, 41]; and 19 
(4) comparison of ABCR in an invited population vs. a neighbouring uninvited one using the percent 20 
reduction in ABCR. This is the case for a single study [42], although the inclusion of neighbouring 21 
nonscreening areas is a secondary part of the design of other investigations [8, 36].         22 
The statistical significance of observed changes, if any, was assessed in 17 studies [8, 13-15, 23 
30-34, 36-41, 43, 44].  24 
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Some information on the trend (before and after the introduction of screening) for the 1 
frequency of unknown-stage cancer was provided by 11 studies [8, 12, 15, 19, 29, 30, 32, 33, 35, 38, 2 
39]. The tumour staging criteria varied. Although 20 studies used the UICC TNM classification there 3 
was little agreement in the definition of advanced breast cancer. In one study, incidence was 4 
presented for multiple stage categories but the advanced category (or categories) was not explicitly 5 
identified [29].               6 
 7 
Study results    8 
A significantly favourable impact on ABCR was reported by nine studies. In the national Dutch study, 9 
ABCR [T2+ with lymph node (N+) and/or distant  metastases (M1)] decreased by 12% [14].  In one 10 
regional Dutch study, the annual IRR varied between 0.86-0.82 (T2+ cancer) and 0.83-0.72 (N+ 11 
cancer) [31]. In the study from Sweden, RRs were 0.74 (tumour size >2 cm), 0.89 (N+ cancer), and 12 
0.84 (Stage II+ cancer) [33]. In the national Finnish study, the ABCR (non-localised cancer) decreased 13 
by 9% [34]. A significant impact on ABCR was observed in three studies from Italy. Paci et al. found a 14 
RR (Stage II+) of 0.72 [30]. The figure reported by Foca et al. for T2+ cancer was between 0.81-0.71 15 
[15]. A secondary observation from a more recent Italian cohort study comparing attenders and non-16 
attenders was a significant ratio of 0.83 between the observed number of T2+ cancers in a whole 17 
invited cohort and the expected number based on pre-screening rates [44]. In a large French study, 18 
the decrease was significant both for T2+ cancer and Stage II+ cancer [43]. In a local study from 19 
Germany, Simbrich et al. demonstrated significant decreases of varying magnitude in annual ABCR 20 
among women aged 50-69 years [40].    21 
Two studies provided unclear results. A Danish study described a transient increase in 22 
incidence of cancers >20 mm in size in early screening regions followed by a decline of N+ cancers in 23 
late screening regions [37]. The Italian study of Buiatti et al. was limited to ≤3 screening years for 24 
most of the participating subareas. After early significant increases in T2+ cancer rates in two of 25 
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them, a moderate reduction was observed 4-6 years after the start of the programme in the area 1 
with longer follow-up [32].  2 
Four nationwide Norwegian studies reported contradictory findings. Kalager et al. observed a 3 
significant IRR (Stage III+ cancer) of 0.76, but the same figure was found in the not-yet invited 4 
population before screening [36]. Also, the reduction was confirmed by a second study but in 5 
association with an increase for Stage II cancer [39]. Others reported the opposite, that is, a decrease 6 
for Stage II cancer and an increase for Stage III cancer [19]. Another study found significant increases 7 
both for Stage II and Stage III cancers and a decrease for Stage IV cancer alone [38]. None of these 8 
studies used individual data indicating whether women were diagnosed before or after they were 9 
invited to participate.      10 
In addition to the abovementioned studies from France [43] and Germany [40], three 11 
investigations used the joinpoint analysis or the Poisson regression analysis. In the West Midlands 12 
(UK), the incidence of N+ cancer increased in the first years of screening and then returned to the 13 
baseline level but with a significant positive APC of 1.1 [13]. In Denmark, the negative APC in 14 
incidence of T2+ cancer was significant but the ratio between post-screening and pre-screening rate 15 
was not significantly different from the unity [8]. In another study from the Netherlands, a non-16 
significant negative APC in Stage 2+ cancer rate was observed but the estimate included the whole of 17 
women aged 50 or older [41].    18 
Four studies, in addition to one of the abovementioned Norwegian studies [19], presented 19 
no assessment of significance of observed changes in ABCR (if any). One Italian study reported a 8.7% 20 
decrease for N+ cancer [29]. In the fifth Norwegian study, ABCR (regional or distant cancer) rose 21 
before the introduction of screening, and fluctuated thereafter at levels that were generally above 22 
the last pre-screening level [35]. In a regional Dutch study, ABCR (Stage IIA+ cancer) was described to 23 
be stable before and after the introduction of screening [12]. In Ireland, ABCR (Stage 2+) in a region 24 
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targeted by screening in 2000 fell by 20% in comparison with a region in which screening was 1 
implemented only seven years later [42].    2 
     3 
Method check          4 
   5 
The right-hand column in Table 2 gives the results of the review of selected papers against the ten-6 
point checklist.  7 
 8 
 Insert Table 2 here –  9 
 10 
The issue of follow up time (#1) is related to the short time window after prevalence 11 
screening where  a decrease in ABCR can be observed. Studies with a long time window, most 12 
notably seven studies [8, 12, 13, 19, 34, 37, 41] in which the time difference between the year of 13 
start of the screening programme and the last year of observation was ≥ 15 years, will not be able to 14 
show this decrease. This is particularly problematic when interpreting annual percent changes [13, 15 
41]. If screening is working as anticipated annual percentage changes will be substantial in the first 16 
years of a programme, but will be small or absent after the programme has achieved widespread 17 
coverage as the new lower incidence will be roughly constant. The related problem of the effect of a 18 
dynamic population on exposure time (#2) applies to all studies. Foca et al. excluded women aged 19 
50-54 years but not new immigrants and late attendees [15]. Anttila et al. provided separate data for 20 
women aged 50-54 years and 55 years or older [34].  21 
The problem due to pace of implementation (#3) applies especially to the Swedish study [33], 22 
the Italian studies [ 15, 29, 30, 32, 44], the nationwide Norwegian studies [ 19, 36, 38, 39], the Danish 23 
studies [8, 37], and the nationwide Dutch study [14]. In fact, it is rare that a mammography service 24 
screening programme is started simultaneously throughout a large geographic area. In two of these 25 
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studies, there was explicit adjustment of the analysis to address this issue. In the Swedish study, the 1 
first screening years in some counties were omitted from analysis because mammography coverage, 2 
or the level of exposure, was still low [33]. In addition, in this study, individual data on screening 3 
exposure was available for the nominal screening period. In the study of Foca et al. the years of 4 
observation were synchronised at the municipality level, and those municipalities where saturation 5 
was not reached within a short (arbitrary) time interval were not taken into consideration [15]. This 6 
proved to be a practical but powerful approach to account for gradual programme implementation. 7 
In other studies, at least some information was available for the reader to assess the potential size of 8 
the problem. The papers reporting the nationwide Dutch study and the Danish study drew the 9 
reader’s attention to this issue by presenting results for individual years and for regions 10 
implementing screening at different times [14, 37]. One of the Italian studies also had individual data 11 
on screening exposure during the nominal screening period [30].   12 
The prevalence effect problem (#4) applies virtually to all studies with markedly stepwise 13 
implementation of the programme. Of the two problems concerning the reference incidence, the 14 
inevitable lack of a verifiable estimate of the underlying background incidence rate (#5) applies to all 15 
studies. Outside of a randomised trial, the estimation cannot be performed without assumptions 16 
regarding the likely incidence of breast cancer, and specifically late stage breast cancer, in the 17 
absence of screening. The problem of its decreasing validity over time (#6) applies especially to those 18 
studies, already mentioned above, in which the time interval between the last prescreening year and 19 
the last year of observation was ≥ 15 years [8, 12, 13, 19, 34, 37, 41]. However, again, presentation of 20 
data for individual years affords the reader a means of assessing the likely extent of underestimation 21 
[37].  22 
Difficulties with the definition of advanced cancer (#7) apply to all studies, because all such 23 
definitions have pros and cons. Some used the pT information alone [8, 15, 44], others used multiple 24 
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advanced stage definitions with separate results [13, 19, 29, 31, 33, 36-39, 43], or a single definition 1 
of advanced stage based on the TNM system [12, 14, 30, 32, 34, 35, 40-42].  2 
Of the two problems concerning tumour stage information, the problem of stage migration 3 
(#8) applies to all studies except those where the definition of advanced cancer was exclusively based 4 
on pT information [8, 15, 44]. More than half of the studies did not take changes in the proportion of 5 
unknown stage information ( #9) into consideration, providing no trend in missing tumour stage data 6 
[12-14, 31, 34, 36, 37, 40-44] or only very partial data [32]. A stable trend was reported by one of the 7 
Italian studies [29]. A percent decrease of incident breast cancers with missing stage information was 8 
observed in other two Italian studies [15, 30], in the Swedish study [33], in three Norwegian studies 9 
[35, 38, 39], and in a study from Denmark [8]. In two of these, the resulting bias was adjusted for in 10 
the design [15] and, respectively, in the analysis [33].  11 
Finally, the problem of a lack of standardised statistical approach (#10) applies especially to 12 
those studies reporting purely descriptive data [29, 35, 42] or incidence curves without numerical 13 
data [12, 19] and those based on the joinpoint analysis [13, 41] and the Poisson regression analysis 14 
[8, 40, 43], the results of which are difficult to interpret.    15 
 16 
DISCUSSION 17 
 18 
The 22 studies included in this review showed considerable variation in results on the estimated 19 
effect of the introduction of population-based mammography screening programmes on the ABCR. 20 
Of note, there are four circumstantial indications that the overall effect of methodological issues 21 
resulted in an underestimation of the impact on ABCR: first, most biases have a conservative 22 
direction (#2, #3, #4, #8, and #9); second, most of the largest studies reported a significant decrease 23 
in ABCR [14, 15, 33, 44]; third, the decrease was more pronounced after some adjustments for 24 
design biases were made [15, 33]; and, fourth, taking the entire series of studies into consideration, 25 
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nine of them found a significant, albeit varying, reduction in ABCR. They represent the majority of 1 
published studies once those affected by critical limitations are excluded. In our opinion, the report 2 
by Buiatti et al. [32], focusing the first 3 years of screening, and the four nationwide Norwegian 3 
studies [19, 36, 38, 39], with their conflicting and partly opposite findings, are difficult to interpret. 4 
Furthermore, the study by Larsen et al. demonstrated clearly that stage-specific incidence of breast 5 
cancer in Norway was influenced by changes in coding and classification practices, which makes it 6 
even more challenging to evaluate and compare stage-specific trends and stage migration of breast 7 
cancer by age and time [19] 8 
Nonetheless, the conclusions of the available literature still warrant careful interpretation, 9 
because not all methodological concerns could be avoided. Also, while the direction of the potential 10 
biases can be predicted, it is difficult and sometimes impossible to estimate their magnitude. Some 11 
of the problems are unavoidable and apply to all studies (specifically #2, #5, #7), whereas others 12 
could potentially be addressed in the design phase. In any case, it would be arbitrary to rank their 13 
consequences in terms of relative impact on study results, which may also vary in relation to local 14 
contingencies. More realistically, we aimed at summarising the challenges in designing studies on 15 
ABCR in order to improve consistency in the reporting of results.  16 
Ideally, the study population should be rapidly saturated by exposure to screening, and this 17 
should take less time than that needed for the expected effect on ABCR to become apparent. From 18 
this point of view population-based service screening programmes often cannot provide this ideal 19 
situation. The dynamic nature of the target populations, together with the phased introduction of 20 
most screening programmes and the fact that the prevalence screen will be associated with an 21 
increase in ABCR, will lead to an underestimate of the decrease in ABCR, as will the reduction in the 22 
proportion of unknown-stage tumours.   23 
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In addition, certain statistical analyses, such as the joinpoint analysis (#10), may generate 1 
false negative results. Conversely, problems of estimation of underlying incidence in the absence of 2 
screening, and particular definitions of advanced stage (#5 and #7) may have been responsible for 3 
unpredictable effects in either direction. Many of the problems also arise from the reliability and 4 
validity of incidence data, in particular the unavailability of reliable reference incidence rates for 5 
advanced cancer, especially in a historical comparison period, together with the sharp decrease in 6 
the proportion of unknown-stage cancers following the introduction of screening. Stage migration 7 
bias, caused by the implementation of sentinel lymph node biopsy between the mid-1990s and early 8 
2000s [18, 19], will also have had an impact.  9 
Furthermore, the inconsistency in the definition of advanced cancers gives rise to difficulties 10 
in interpreting the collected evidence. There is a possibility of a residual improvement within stage 11 
categories, but this is more difficult to demonstrate. The consistency between studies in the use of 12 
tumour diameter, stage and other parameters was limited. Another limitation in the classification of 13 
advanced cancers, especially in studies performed nowadays, is the variation among cancer registries 14 
(and within cancer registries over time) in what clinical and pathological data they collect. There is 15 
growing interest in the effect of screening, if any, on biological and molecular markers, but it will be 16 
some time before sufficient data are generated to answer this question. Incidentally, we believe that 17 
deficiencies in staffing, organisation, access, and funding of ongoing mammography service screening 18 
programmes warrant much greater consideration in the debate about their effectiveness. 19 
From a scientific point of view, however, the most severe limitations of reviewed studies (#1 20 
to #4) affected the study design. The main departures from the ideal design of a temporal correlation 21 
study were the following. First, as shown in the Swedish Two-County trial [2, 15], the time window 22 
available to observe an impact (if any) on ABCR closes rapidly. In populations where screening has 23 
been ongoing for a longer time [12, 13, 41], analysis should focus on establishing whether incidence 24 
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of advanced disease is lower than before, not ‘still decreasing’. The misuse of the joinpoint analysis 1 
and of the Poisson regression analysis (#10) is itself related to the assumption that the downward 2 
incidence trend must continue indefinitely [13]. This cannot be the case, unless a substantial increase 3 
of mammography sensitivity occurs over time. Second, the 3-year latency of the effect of screening 4 
on ABCR means that, in the dynamic target population of a service screening programme, at any 5 
point in time, there is always a subset of women with an exposure time to screening that is too short 6 
to have an effect on the risk of advanced breast cancer. Third, and more important, service screening 7 
programmes in Europe were introduced very gradually. This inevitably caused the same dilution of 8 
effects as that historically described for cervical cancer screening in Denmark and Norway as 9 
compared with Finland and Sweden [34].   10 
In fairness, most of the studies reviewed either attempted to control for possible problems 11 
by adjustment in statistical analysis or presented data in sufficient detail for the reader to judge the 12 
likely presence and direction of potential biases. There have been surprisingly few attempts, on the 13 
other hand, to adjust the design to minimise biases. The only previous literature review on ABCR 14 
following the introduction of mammography screening programmes did not take into consideration 15 
the limitations of published articles, except for the stage migration bias [5, 19]. The authors 16 
concluded that trends in advanced breast cancer incidence do not support a role for screening in the 17 
decrease in mortality. The present work demonstrates that the available literature cannot support 18 
such a conclusion, and indeed supports the opposite.  19 
 20 
CONCLUSIONS 21 
In summary, all studies were challenged by multiple issues, although to a varying extent. The trend in 22 
most of evaluable results, even though inconsistent, does support a reduction in advanced breast 23 
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cancer incidence following the introduction of mammography screening. In view of the impact on 1 
ABCR observed in RCTs [1], we conclude that much of the current controversy on mammography 2 
service screening programmes is due to observational data that were gathered and/or analysed with  3 
methodological approaches which could not capture stage effects in full [27, 28]. Notwithstanding 4 
this fact, changes in ABCR remain an important early indicator of effectiveness. Improving the 5 
knowledge of limitations in previous studies will help to establish consensus on the correct 6 
methodology. The development of more robust and empirically driven techniques should take into 7 
account both the practical implementation of cancer screening activities and the evaluation of their 8 
effects. This will enable a better fit of the design of studies on ABCR to the particular context of a 9 
mammography service screening programme. 10 
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LIST OF ABBREVIATIONS 1 
ABCR: advanced breast cancer rate;  2 
APC: annual percent change; 3 
CI: confidence interval;   4 
EAPC: estimated annual percent change;  5 
IRR: incidence rate ratio;  6 
M1: distant spread;   7 
N+: node-positive; 8 
NA: not applicable; 9 
NOS: not otherwise specified;   10 
NR: not reported;  11 
NS: not significant;    12 
O:E: observed:expected;  13 
pT: pathologic tumour size category;  14 
RCT: randomized controlled trial; 15 
RR: relative risk; 16 
S: significant;  17 
SOSSEG: Swedish Organised Service Screening Evaluation Group;  18 
T2+: tumour size >2cm;  19 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
TNM: Tumour, Node, Metastasis;        1 
TX: unknown tumour size;  2 
UICC: Unione Internationale Contre le Cancer; 3 
UK: United Kingdom; 4 
W: women 5 
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LEGENDS  1 
 2 
Tables 1 and 2 and figure 2 in this paper are original for this article. 3 
Figure 1 is reproduced with permission from Foca et al. [15].  4 
 5 
Figure 1. Expected effect of mammography service screening on the occurrence of advanced breast 6 
cancer, illustrated by Figure 2, right panel, from Foca et al. [15]. Ratios with 95% confidence intervals 7 
are illustrated between the observed and expected age-standardised incidence rates of breast cancer 8 
per 100,000 women according to 2-year screening period (ages 55 to 74 years). pT indicates 9 
pathologic tumour classification.  10 
 11 
Figure 2. Flowchart of search strategy and selection of papers  12 
 13 
Table 1. Characteristics of the screening programmes, and design and results of studies of the impact 14 
of mammography screening on the incidence of advanced breast cancer    15 
 16 
Table 2. Ten-point checklist of main methodological problems affecting studies of the effect of 17 
mammography screening programmes on the incidence of advanced breast cancer 18 
19 
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Table 1.   Characteristics of the screening programmes, and design and results of studies of the impact of mammography screening on the incidence of advanced breast cancer    
 
Study generalities    
 
 
 
 
First author Barchielli A   Paci E  Schouten LJ  Buiatti E 
Year of publication 2001 2002 2002 2003 
Country Italy Italy The Netherlands Italy 
Regional area(s) Florence area (city of Florence and 
surrounding municipalities)  
City of Florence Limburg 7 areas in central and northern Italy 
The screening programme     
 Target age (years) 50-69 50-69 49-69 (49-75 since 1998 )  50-69 
Target population 164,000b  60,000 NR 1,033,000  
Screening interval (mos) 24 24 24 24 
Year of start Some municipalities, early 1970s; 
city of Florence, 1990; other 
municipalities, after 1992       
1990 1990  Locally varying between 1990-98 
Year of saturationa  After the end of the time period of 
observation (see Remarks) 
1993  1994 After the end of the time period of 
observation  
Response rate 60% NR First invitation, annually 25-82%; 
subsequent invitations, 77-85%  
65% [15] 
Study design and results     
 Time period of observation  1985-94 1985-96 1987-99 Prescreening years, locally varying 
between 1988-97; screening years, 
locally varying between 1990-99   
Design Study of all-age incidence by stage in 
1985-87, 1988-90, and 1991-94, 
with a focus on W aged 50-69   
Study comparing ABCR in 1990-96 
(screening period) vs 1985-86 
(prescreening period), and in invited 
W vs noninvited W   
Study comparing ABCR in each year 
1987-99 (screening years) vs 1987-
90 (prescreening period)             
Study comparing ABCR in the screening 
period vs the prescreening period, by 
area, in W aged 40-79    
Endpoint % change in incidence rates, by 
stage, in 1991-94 vs 1985-87 
% and absolute reduction in ABCR, 
and invited:noninvited RR            
IRR    IRR         
Tumour staging Tumour spread (local, regional, 
distant)     
UICC TNM UICC TNM     UICC TNM 
Definition of advanced stage None specified Stage II+  Distinct definitions: T2+, N+     Tumour size >2 cm or N+ or Stage IV 
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Frequency of unknown stage 
cancer 
Unknown tumour spread, stable 
incidence rate      
Unknown stage: 1985-86, 14%; 
1990-96, 7% 
NR      Unknown stage, 6% with a significant 
reduction in the screening period in one 
area 
Results W aged 50-69: regional, -8.7% 
(significance, NR); distant, NR      
% reduction in ABCR, -19; absolute 
reduction, -3.6 per 10,000; RR, 0.72 
(95% CI, 0.59-0.87)       
T2+: increase in 1991 (IRR, 1.22; 95% 
CI, 1.09-1.37), decrease in 1998 
(0.86; 0.77-0.97) and 1999 (0.82; 
0.73-0.92). N+: increase in 1991 
(IRR, 1.28; 1.13-1.45), decrease in 
1995 (0.83; 0.73-0.94) and 1999 
(0.72; 0.63-0.81)           
IRR by area, from 0.91 (p = 0.07) to 1.21 
(p = 0.02)  
 
  Remarks By 1995, only part of municipalities 
of the Florence area were targeted 
by screening   
  The study was limited to ≤3 screening 
years for 5/7 areas. A moderate 
reduction in ABCR was observed 4-6 
years after the start of the programme 
in one area     
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Table 1. CONTINUED  
 
Study generalities    
 
 
 
 
First author Fracheboud J SOSSEG Anttila A  Hofvind S 
Year of publication 2004 2007 2008 2008 
Country The Netherlands  Sweden Finland Norway 
Regional area(s) NA (nationwide study)  13 counties NA (nationwide study) Rogaland, Akershus, Hordaland, and 
Oslo counties  
The screening programme     
 Target age (years) 50-69 Locally varying between 40-74  Mainly 50-59   50-69 
Target population 813,000 in 1997 [45]  4,403,000 person-years     NR NR 
Screening interval (mos) 24 24 in most counties 24 24 
Year of start Utrecht and Nijmegen regions (“old” 
regions), mid-1970s; the 7 remaining 
regions (“new” regions), 1990-91      
Locally varying between 1988-96 
 
1987 Rogaland county, 1995; Akershus, 
Hordaland, and Oslo counties, 1996 
Year of saturationa  Approximately 1994      NA 1992 NR 
Response rate 78% [45]     70-90% [46]   NR First 10 years, national average 76%   
Study design and results     
 Time period of observation  1989-97 Prescreening epoch, locally varying 
between 1968-95; screening epoch, 
locally varying between 1988-2001 
(see Remarks) 
1971-2002 1987-2004 
Design Study of all-age incidence in each 
year 1990-97 vs 1989, by group of 
regions, with a focus on W aged 50-
69             
Study comparing advanced cancer 
risk in the screening epoch vs the 
prescreening epoch (W aged 40-69)    
Study comparing the observed ABCR 
in the years 1998-2002 with that 
expected based on extrapolation of 
rates from 1971 to 1986 in 5-year 
age groups between 50-69     
Study of ABCR in 1987-95 (prescreening 
period) and 1996-2004 (screening 
period)         
Endpoint EAPC in ABCR          RR of advanced cancer adjusted for 
the proportion with missing stage 
data and the increase in underlying 
incidence    
Excess RR in %      ABCR  
Tumour staging UICC TNM  UICC TNM  Tumour spread (localised, non- Tumour spread (local, regional, distant) 
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localised). Non-localised (or 
regional/distant) spread mainly 
based on lymph node status    
Definition of advanced stage T2+ and (N+ and/or M1)    Distinct definitions: tumour size >2 
cm, N+, Stage II+  
Non-localised spread Regional or distant spread   
Frequency of unknown stage 
cancer 
TX, between 2.1% and 3.2% annually 
(no time trend data)      
Tumour size unknown: prescreening 
epoch, median among counties 12%; 
screening epoch, 1%b       
Unknown stage (NOS), 9.4% (no 
time trend data) 
Unknown regional spread, NR. 
Unknown distant spread: 1987-95, 2%; 
1996-2004, 7%b       
Results EAPC in ABCR: new regions, +3 up to 
1994 and -2.14 (95% CI, -3.47 to -
0.80) between 1995-97, for a total 
of -12.1 in 1997 vs 1989 (63.0 vs 
71.6/100,000); old regions, -5.5 (-
8.52 to -2.37)         
RR of tumour size >2 cm, 0.74 (95% 
CI, 0.69-0.79); RR of N+, 0.89 (0.84-
0.95); RR of Stage II+, 0.84 (0.79-
0.89) 
Excess RR: W aged 50-54, -6% (NS); 
W aged 55-59, -18% (S); W aged 64-
64, -21% (S); W aged 65-69, -16% 
(S); total, -9% (S)            
ABCR, increase from 75 to 86 in 1987-
95, 98 and 96 in 1996 and 1997, 
fluctuation between 84 and 99 in 1998-
2005 (significance, NR)    
 Remarks  In 5 counties, the prescreening and 
screening epochs were not 
contiguous, in order to have a 
coverage close to zero and 100%, 
respectively     
The implementation of the 
programme had a stepwise 
“pseudo-randomized” design for 
evaluation purposes 
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Table 1. CONTINUED  
 
Study generalities    
 
 
 
 
First author Autier P  Kalager M  Nederend J Foca F  
Year of publication 2012 2012 2012 2013 
Country England Norway The Netherlands Italy 
Regional area(s) West Midlands NA (nationwide study) Southern region 700 municipalities in 6 administrative 
regions of central and northern Italy  
The screening programme     
 Target age (years) 50-64 50-69 50-75  50-69 
Target population NR  NR NR 693,000    
Screening interval (mos) 36 24 24 24 
Year of start 1988 4 counties, 1996; the remaining 15 
counties, over the following 9 years     
1990-91 [14]     Locally varying between 1991-2005 
Year of saturationa  1991  2005 NR NA (see Design) 
Response rate 1992-94, 70%; 1995-2004, 75%b    77%  NR 65%  
Study design and results     
 Time period of observation  1989-2004 (no prescreening years) 1986-2005 1980-2008 Locally varying between 1990-2006  
Design Joinpoint regression analysis of time 
trend in  annual ABCR        
Study comparing ABCR in the invited 
population (1998-2005, i.e. 
excluding the prevalence round) 
with the prescreening population 
(1987-95)  
Study of ABCR in each year 1980-
2008             
Study comparing observed ABCR with 
expected (prescreening) ABCR, by year 
of screening (W aged 55-74). For each 
municipality, the screening years were 
numbered from 1 to 8 
Endpoint APC    IRR   
 
No numerical endpoints: curve of 
ABCRs as a marginal information in a 
study of the prevalence of advanced 
cancer among screened W     
IRR   
Tumour staging UICC TNM UICC TNM UICC TNM     UICC TNM   
Definition of advanced stage Distinct definitions: tumour size >50 
mm, N+  
Stage III+   Stage IIA+     T2+  
Frequency of unknown stage 
cancer 
NX, 20% (no time trend data)  NR Unknown stage: screen-detected 
cancers, 0.1% (stable); interval 
TX: year 1, 10%; year 2, 9%; thereafter, 
<5%   
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cancers, 0%; others and 
prescreening, NR 
 Results >50 mm in size: APC, 0.2 (95% CI, -
2.2 to 2.7) in 1989-2004. N+: 
increase in ABCR in 1989-92, 
decrease in 1993-95, stable return 
to the level of 1989 in 1995-2000; 
APC, -0.7 (-1.8 to 0.3) in 1989-2004, 
1.1 (0.1-2.0) in 1992-2004  
IRR, 0.76 (95% CI, 0.61-0.91)  
 
Curve interpreted as showing that 
ABCR was stable between 1980-
2008 and did not decline after the 
introduction of screening          
IRR: no significant changes in years 1-2, 
between 0.81 (95% CI, 0.75-0.88) and 
0.71 (0.64-0.79) from years 3-4 onward 
 Remarks ABCRs were calculated with a 33-
step procedure using total incidence 
data (http://ci5.iarc.fr)  and 
published tumour stage data from 
the screening programme [47, 48]      
An IRR of 0.76 (95% CI, 0.61-0.91) 
was also observed in not-yet invited 
population (1996-2003 vs 1986-94)       
 Eligibility was restricted to those 
municipalities in which the proportion 
of total incident cancers that were 
screen-detected (a proxy of saturation) 
reached the arbitrary level of 30% 
within year 2 
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Table 1. CONTINUED  
 
Study generalities    
 
 
 
 
First author Christiansen P Lousdal ML Lousdal ML Simbrich A 
Year of publication 2014 2014 2016 2016 
Country Denmark Norway Norway  Germany 
Regional area(s) NA (nationwide study) NA (nationwide study) NA (nationwide study) Münster district 
The screening programme     
 Target age (years) 50-69 50-69 50-69 50-69 
Target population NR NR NR NR 
Screening interval (mos) 24 24 24 24 
Year of start Old regions: Copenhagen 
municipality, 1991; Funen county, 
1993. Late regions: Bornholm 
municipality, 2001; West Zealand 
county, 2004; the remaining areas, 
2007    
One county, 1995; the remaining 18, 
during the following 9 years     
1995 2005 
Year of saturationa  2010 2004 2004 2008 
Response rate First screen: Copenhagen, 71%; 
Funen, 85%. Subsequent screens: 
Copenhagen, 62%; Funen, 82%  
76% [35]   76% [35]   55% 
Study design and results     
 Time period of observation  1990-2011 both for early and late 
screening regions    
1987-2010 1987-2011 2000-13 
Design Study of all-age incidence by stage, 
with a focus on W aged 50-69 
Study of all-age incidence comparing 
ABCR in 2005-10 (screening period) 
vs 1987-95 (prescreening period), 
with a focus on W aged 50-69     
Open cohort study of ABCR in W 
eligible for screening vs the historic 
(prescreening) population of W of 
the same age   
Log-linear Poisson regression analysis of 
time trend in ABCR in 2006-08 
(implementation phase) and 2009-13 by 
5-year age group between 45-79      
Endpoint ABCR   IRR IRR  Slope value from the log-linear Poisson 
regression model (average annual 
change), and absolute ABCR difference 
(2013 vs 2000)      
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Tumour staging UICC TNM UICC TNM     UICC TNM UICC TNM  
Definition of advanced stage Distinct definitions: tumour size >20 
mm, N+  
Distinct definitions: Stage II, Stage 
III, Stage IV     
Distinct definitions: Stage II, Stage 
III+ 
Stage II+ 
Frequency of unknown stage 
cancer 
NR Unknown stage: 1987-95, 9%; 2005-
10, 4%   
Missing information (NOS): 1987-94, 
30%; 1995-2002, 19%; 2003-11, 7%   
TX and/or NX, 10% (no time trend data)    
Results >20 mm in size, transient increase in 
2008-09 in old screening regions; 
N+, significant decline from 117 in 
2001-07 to 98 in 2010-2011 in late 
screening regions  
Stage II: IRR, 1.47 (95% CI, 1.40-
1.55). Stage III: IRR, 1.32 (1.13-1.55). 
Stage IV, 0.67 (0.57-0.68). Total 
advanced: IRR, 1.35 (1.29-1.42) 
              
Stage II: IRR, 1.26 (95% CI, 1.21-
1.31). Stage III+: IRR, 0.80 (0.74-
0.87) 
Average annual change (2009-2013): W 
aged 50-54, 0.016 (95% CI, -0.024 to 
0.056); W aged 55-59, -0.054 (-0.095 to 
-0.014); W aged 60-64, -0.089 (-0.128 to 
-0.050); W aged 65-69, -0.113 (-0.153 to 
-0.073).  
Absolute ABCR difference (2013 vs 
2000): W aged 50-54, -0.002 (-0.191 to 
0.187); W aged 55-59, -0.346 (-0.533 to 
-0.160); W aged 60-64, -0.279 (-0.454 to 
-0.105); W aged 65-69, -0.320 (-0.515 to 
-0.126) 
  Remarks    IRRs for W aged 20–49, who were 
presented as a control group for 
time trends in stage-specific 
incidence, were similar to those for 
W aged 50-69 
Missing stage values were multiply 
imputed. We report unadjusted 
estimates, since the purpose and 
necessity of adjustment were not 
clear. For each analysis, the IRRs for 
the screening vs historic group were 
also compared with the IRRs for the 
younger (ineligible) vs younger 
historic group. The unadjusted 
relative IRR was 1.14 (95% CI, 1.07-
1.22) for Stage II and 1.00 (0.87-
1.15) for Stage III+ 
 
   
Missing stage values were multiply 
imputed 
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Table 1. CONTINUED  
 
Study generalities    
 
 
 
 
First author Autier P Hanley JA  Jørgensen KJ Molinié F 
Year of publication 2017 2017 2017 2017 
Country The Netherlands  Ireland  Denmark France 
Regional area(s) NA (nationwide study) 23 out of 26 counties  NA (nationwide study) Hérault, Isère, Loire-Atlantique 
The screening programme     
 Target age (years) 50-69 (50-75 since 1997) 50-64 50-69 50-74 
Target population NR NR 703,289 NR 
Screening interval (mos) 24 24 24 24 
Year of start 1988 11 counties, 2000 (Region 1); 12 
counties, 2007 (Region 2)   
Locally varying between 1991-2007  Locally varying during the 1990s 
Year of saturationa  NR NR Coverage still incomplete at the end 
of the time period of observation  
NR  
Response rate Around 80% 68-76% 62- 82%  NR 
Study design and results     
 Time period of observation  1989-2012 2000-13 1980-2010   2000-10 
Design Multi-objective study, with a 
joinpoint regression analysis of time 
trend in  annual ABCR 1989-2012 for 
W aged ≥50   
 
Multi-objective study, with a 
comparison of annual ABCR 
between Region 1 and Region2     
Multi-objective study, with a 
Poisson regression analysis of time 
trend in annual ABCR 1980-2010 
 
Poisson regression analysis of time 
trend in ABCR in 2000-10 among W 
aged 20-49, 50-74, and 75 and older 
Endpoint APC ABCR in Region 1 minus ABCR in 
Region 2 as a percentage of the 
latter   
APC, and ABCR ratio before and 
after the introduction of screening, 
both in the screening and 
nonscreening areas         
APC  
Tumour staging UICC TNM UICC TNM  UICC TNM UICC TNM  
Definition of advanced stage Stage 2+      Stage 2+   T2+  Distinct definitions: T2+, Stage II+       
Frequency of unknown stage 
cancer 
Unknown stage: 2009-11, 1%  (no 
time trend data) 
NR TX: 1980-2004, 8-10%; 2004-10, 4-
5%   
TX, 3% (no time trend data) 
Results APC, -0.16 (95% CI, -0.36 to 0.04) ABCR, 20% lower in Region 1 in 2007 Screening areas. APC in ABCR: W aged 50-74. T2+: APC, - 1.9 (95% CI, -
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(significance, NR) and then 
narrowing   
before screening, -0.5 (95% CI, -1.9 
to 0.9); after screening, -1.1 (-1.8 to 
-0.3). ABCR ratio, 0.96 (0.90 to 1.02)        
2.8 to -1.0). Stage II+: APC, -2.0 (-2.7 to -
1.3)      
 Remarks Stage 2+ probably indicates T2+, 
since a tumour size of 20 mm is 
referred to as the threshold size to 
distinguish between Stage 1 and 2    
It is not clear whether Stage 2+ 
indicates Stage II+  
Nonscreening areas. APC in ABCR: 
before screening, 1.7% (95% CI, 
0.8% to 2.6%); after screening, 3.0% 
(2.6% to 3.3%). ABCR ratio, 1.46 
(1.41 to 1.52) 
Overall, a 20.9% linear decrease in T2+  
cancer over 11 years in the three 
screening areas were noted for W aged 
50-74. No change in ABCR was found in 
younger or older W 
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Table 1. CONTINUED  
 
Study generalities  
 
 
 
 
First author Puliti D   Larsen IK 
Year of publication 2017 2018 
Country Italy Norway 
Regional area(s) Nine health care districts in central 
and northern Italy  
NA (nationwide study) 
The screening programme   
 Target age (years) 50-69  50-69 
Target population 413,000 NR 
Screening interval (mos) 24 24 
Year of start Locally varying between 1991-98  1996 
Year of saturationa  Locally varying between 1993-2000 2005 
Response rate NR 75% 
Study design and results   
 Time period of observation  Locally varying between 1991-2011 1980-2015 
Design Cohort study of ABCR in attenders 
to screening vs non-attenders, with 
a comparison of the observed 
number of ABC among W invited 
with that expected based on  
prescreening ABCR     
Study of all-age stage-specific 
incidence based on different staging 
systems, with a focus on W aged 50-
69   
Endpoint O:E ratio No numerical endpoints: curve of 
ABCRs      
Tumour staging UICC TNM UICC TNM 
Definition of advanced stage T2+   Distinct definitions:  
Stage II, Stage III, Stage IV 
Frequency of unknown stage 
cancer 
TX, 10-29% (no time trend data)   Unknown stage, 40% with an 
apparent increase in the first half of 
the time period of observation and 
an apparent decrease in the second   
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Results T2+: O:E ratio, 0.83 (95% CI, 0.80-
0.86)  
Curves interpreted as showing an 
incidence decrease for Stage II and 
an increase for Stage III 
 Remarks The O:E ABC ratio was estimated for 
the purposes of assessment of self-
selection bias  
 
 
a Year of saturation: the year by which all women in the initial target population were invited at least once.     
b Indirectly derived or calculated from numbers, tables, and figures in the paper.    
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Table 2. Ten-point checklist of main methodological problems affecting studies of the effect of mammography screening programmes on the incidence of advanced breast cancer  
 
Point # Issue Problem Consequence Potentially affected  
studies (reference 
number) 
1 Follow up time  The time window available to observe a decrease (if any) in ABCR is 
narrow and closes rapidly. In the Two-County trial, ABCR in the 
study group began to decrease 4 years after randomization and 
stabilized at a lower level on the 8th year [2]. 
 
The ABCR is expected to increase with the prevalence screening, it 
may fall in the years immediately following the prevalence screen,  
and will likely be stable at the end of screening in a cohort of 
women. In trend and dynamic population analysis, in the absence of 
an individual time zero (time at entry), the effect is confounded and 
the effect of screening on ABCR is underestimated. This is 
particularly applicable to estimates of annual percent change. 
8, 12, 13, 19, 34, 37, 
41 
2 Exposure time   The target population is a dynamic one (but the same holds true for 
cohort studies). Because there is a latency for the effect of 
screening on ABCR to take place, at any point in time there are 
women (i.e., new quinquagenarians, new immigrants, and late 
attendees) with insufficient exposure time. 
   
The effect of screening on ABCR is underestimated, due to a 
disproportionate influence of prevalence screens. 
All studies 
3 Pace of 
implementation 
Public health screening programmes are implemented gradually, in 
a markedly stepwise fashion, since large populations are divided in 
distinct administrative units each targeted by an independent local 
plan of action.   
The effect of screening on ABCR is diluted. Until implementation is 
completed, there are women who are diagnosed with breast cancer 
before being invited, and who greatly contribute to ABCR.             
8, 14, 15, 19, 29, 30, 
32, 33, 36-39, 44 
 
 
 
4 Prevalence 
effect 
The prevalence screen may be associated with a transient increase 
in ABCR [13].  
During a stepwise implementation of the programme, when the 
time elapsed from the start is theoretically sufficient to see a 
decrease in ABCR, this is counteracted by an opposite effect due to 
newly enrolled women – especially if invitations increase over time. 
 
8, 14, 15, 19, 29, 30, 
32, 33, 36-39, 44 
 
 
 
5 Reference 
incidence (i) 
The reference (or underlying) incidence rate, with which to 
compare the rate observed after the introduction of screening, is 
not known with precision [49].  
The rate can be estimated using the rate observed in the last few 
years before screening, assuming its stability over time, or by linear 
extrapolation of a pre-existing trend. The second approach is 
arguably preferable, but both are dependent on underlying 
assumptions about trends or absence of trends in incidence, and 
All studies 
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results can vary depending on these assumptions. 
6 Reference 
incidence (ii) 
Whatever incidence rate is being used as a reference, its validity 
decreases with increasing number of years of observation due to 
uncontrollable changes (or in the pace of such changes) in the 
underlying risk of breast cancer. 
Assessing the long-term effect of screening on ABCR is subject to 
considerable uncertainty and there is potential for inaccuracy in 
either direction (overestimation or underestimation of effect). 
 
8, 12, 13, 19, 34, 37, 
41 
 
7 Definition of 
advanced 
cancer   
There is no agreed definition of advanced breast cancer [50], even 
though there is general agreement that large or metastatic cancers 
are ‘late stage’.  
 
 
The definition is chosen based on differing criteria. The pT 
information alone, which is the most available one, is direct and 
relatively unaffected by biases due to confounding. Conversely, 
multiple-stage data are more meaningful, since the effect of 
screening may differ across different categories of advanced 
cancers. 
All studies 
8 Stage migration   The introduction of sentinel lymph node biopsy between mid-1990s 
and mid-2000s caused a substantial increase in the registered 
incidence of node-positive breast cancer (stage migration bias) [18].  
The use of pN staging is problematic in studies of trends in ABCR 
over the last two decades, since changes in the risk of node-positive 
cancer cannot affected by stage migration. The increase in node-
positive disease is likely to be population-specific and will depend on 
the rate of change of local surgical policy. However, reductions in 
node-positive disease as a results of screening are likely to be 
underestimated rather than overestimated due to the stage 
migration. 
12-14, 19, 29-43  
 
 
9 Missing data on 
tumour stage    
Whatever staging system is being used, the introduction of a 
screening programme tends to bring an improved quality of breast 
cancer registration, with a sharp decrease in the proportion of 
unknown-stage cancers. 
Because more cases are increasingly placed in all known-stage 
categories, an apparent increase in all stage-specific rates occurs – 
including ABCR.  
8, 15, 30, 32, 33, 38, 
39,   
10 Statistical 
approach 
The statistical approach is not standardised, and includes the 
provision of purely descriptive information and the use of methods 
which are difficult to interpret, such as joinpoint analysis. 
Descriptive information does not allow evaluation of the magnitude 
and significance of observed changes in ABCR. Methods like the 
joinpoint analysis are useful for assessing the points in time when 
ABCR begins to decrease and when it stabilizes, but may be 
misleading when used to assess the significance of the trend. Also, 
the important issue is arguably what happened to ABCR following 
the screening rather than at what point a change occurred in the 
direction of a trend, which is affected by both confounding and 
analytic assumptions. 
8, 12, 13, 19, 29, 35, 
40-43 
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Figure 1 Click here to download Figure Figure 1 - 3 July 2018.TIF 
7   Key papers   8644  English-language papers identified by search strategy in                     
used to build   Pubmed; reviewed to define eligibility for further review (selection  
the search   by one reviewer,  random check of 290 different titles (~10%) by two 
strategy    other reviewers (5% each reviewer)) 
 
     8424  Abstracts excluded   
 
 
220 Abstracts reviewed to define eligibility for further review (each 
abstract was reviewed by two different reviewers)  
 
     158  Abstracts excluded  
        38  Abstracts included 
           24 Abstracts undecided (possible / disagreements) 
 
Review of full papers to clarify eligibility of abstracts (four 
reviewers looked at  12  possibles/disagreements so that 
each one was reviewed by two different reviewers as above 
(where possible 2nd reviewers  looked at papers that they 
hadn’t looked at in 1st review) 
        
20  Abstracts excluded 
           
  
 
    
4 Abstracts included after second review 
 
1 Paper suggested by co-author  
 
 50  Full papers reviewed (each paper was reviewed by two 
different reviewers) 
 
Review of 10 additional papers identified from references 
          5 Papers excluded 
        55                5 Papers selected  
 
24 Papers excluded 
9 Papers – proportions of advanced cancers 
 
 
 
        22 Papers – incidence rates of advanced cancer 
Figure 2 Click here to download Figure Figure 2 - flow chart - 3 July
2018.pdf
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